Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α

[1]  E. Estey,et al.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.

[2]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[3]  D. Mottet,et al.  CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.

[4]  F. Lo‐Coco,et al.  retroviral gene transfer into purified murine hematopoietic progenitors PML-RAR induces promyelocytic leukemias with high efficiency following , 2002 .

[5]  Mircea Ivan,et al.  Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Lallemand-Breitenbach,et al.  How acute promyelocytic leukaemia revived arsenic , 2002, Nature Reviews Cancer.

[7]  V. Praloran,et al.  Hypoxia Modifies Proliferation and Differentiation of CD34+ CML Cells , 2002, Stem cells.

[8]  M. Tallman,et al.  Acute promyelocytic leukemia: evolving therapeutic strategies. , 2002, Blood.

[9]  M. Lanotte,et al.  Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes , 2001, Oncogene.

[10]  G. Semenza,et al.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. , 2001, Trends in molecular medicine.

[11]  P. Fisher,et al.  Differentiation therapy of human cancer: basic science and clinical applications. , 2001, Pharmacology & therapeutics.

[12]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[13]  I. Weissman,et al.  Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor α Chimeric Protein (Pmlrarα) to Block Neutrophil Differentiation and Initiate Acute Leukemia , 2001, The Journal of experimental medicine.

[14]  P. Iversen,et al.  Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats , 2000, Cell proliferation.

[15]  V. Praloran,et al.  Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent , 2000, Transfusion.

[16]  R. Berger,et al.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Zwiebel.  New agents for acute myelogenous leukemia , 2000, Leukemia.

[18]  Y. Huang,et al.  Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia , 2000, Leukemia.

[19]  R. Berger,et al.  Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations , 1999, Leukemia.

[20]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[21]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[22]  F. Mandelli,et al.  Acute promyelocytic leukemia: a curable disease , 1998, Leukemia.

[23]  Y. Fujii‐Kuriyama,et al.  Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[25]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[26]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[27]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[28]  G. Semenza,et al.  Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. , 1993, The Journal of biological chemistry.

[29]  N. Kamada,et al.  Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. , 1991, Blood.

[30]  P. J. Hurley,et al.  Cobalt chloride in the treatment of refractory anaemia in patients undergoing long-term haemodialysis. , 1975, Australian and New Zealand journal of medicine.

[31]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[32]  David I Stuart,et al.  Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. , 2002, Nature.

[33]  S. Shi.  Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia , 2002 .

[34]  P. Pandolfi,et al.  Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide , 2001 .

[35]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.